MX2021005428A - Compuestos de anillo fusionado. - Google Patents
Compuestos de anillo fusionado.Info
- Publication number
- MX2021005428A MX2021005428A MX2021005428A MX2021005428A MX2021005428A MX 2021005428 A MX2021005428 A MX 2021005428A MX 2021005428 A MX2021005428 A MX 2021005428A MX 2021005428 A MX2021005428 A MX 2021005428A MX 2021005428 A MX2021005428 A MX 2021005428A
- Authority
- MX
- Mexico
- Prior art keywords
- fused ring
- ring compounds
- compounds
- inhibition
- administration
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| PCT/US2019/060578 WO2020097537A2 (en) | 2018-11-09 | 2019-11-08 | Fused ring compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005428A true MX2021005428A (es) | 2021-06-15 |
Family
ID=69232886
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005428A MX2021005428A (es) | 2018-11-09 | 2019-11-08 | Compuestos de anillo fusionado. |
| MX2025002980A MX2025002980A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2025002975A MX2025002975A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2025002979A MX2025002979A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2024008118A MX2024008118A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado. |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002980A MX2025002980A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2025002975A MX2025002975A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2025002979A MX2025002979A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado |
| MX2024008118A MX2024008118A (es) | 2018-11-09 | 2021-05-07 | Compuestos de anillo fusionado. |
Country Status (33)
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3871673B1 (en) | 2018-10-26 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
| CN112585129B (zh) | 2019-05-21 | 2022-03-01 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| US11697657B2 (en) | 2019-10-28 | 2023-07-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS G12C mutant |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202214253A (zh) | 2020-06-18 | 2022-04-16 | 美商銳新醫藥公司 | 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法 |
| BR112023002591A2 (pt) * | 2020-08-12 | 2023-04-04 | Genentech Inc | Processo para a preparação de um composto e composto |
| JP2023538060A (ja) * | 2020-08-17 | 2023-09-06 | 貝達薬業股▲ふん▼有限公司 | 二環化合物、それを含む組成物、及びそれらの使用 |
| AU2021331492A1 (en) | 2020-08-28 | 2023-04-13 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023540809A (ja) | 2020-09-11 | 2023-09-26 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤の結晶形態 |
| IL301524A (en) | 2020-09-23 | 2023-05-01 | Erasca Inc | Tricyclic pyridones and pyrimidones |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| EP4240489A4 (en) * | 2020-11-03 | 2024-09-25 | Mirati Therapeutics, Inc. | KRAS-G12D INHIBITORS |
| AU2021377810B2 (en) * | 2020-11-13 | 2025-01-02 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors |
| MX2023005530A (es) * | 2020-11-13 | 2023-05-25 | Genentech Inc | Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon. |
| TW202229285A (zh) * | 2020-11-20 | 2022-08-01 | 大陸商北京加科思新藥研發有限公司 | Kras g12d抑制劑 |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20220193077A1 (en) * | 2020-12-08 | 2022-06-23 | Genentech, Inc. | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors |
| IL303446A (en) | 2020-12-15 | 2023-08-01 | Mirati Therapeutics Inc | Azaquinazoline compounds as PAN-KRas inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| TWI894413B (zh) * | 2020-12-22 | 2025-08-21 | 大陸商上海科州藥物股份有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| JP2024506329A (ja) * | 2021-02-09 | 2024-02-13 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| IL304986A (en) * | 2021-02-16 | 2023-10-01 | Theras Inc | Compositions and methods for inhibition of ras |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| US20240239788A1 (en) * | 2021-04-16 | 2024-07-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12d mutant |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| CN117337193A (zh) * | 2021-05-19 | 2024-01-02 | 基因泰克公司 | 组合疗法 |
| WO2022247760A1 (zh) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| US20240261444A1 (en) * | 2021-05-26 | 2024-08-08 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| TW202325284A (zh) * | 2021-08-18 | 2023-07-01 | 大陸商北京加科思新藥研發有限公司 | N-環丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202327569A (zh) | 2021-09-01 | 2023-07-16 | 瑞士商諾華公司 | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 |
| WO2023097194A2 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic compounds and methods of use |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| JP2025500430A (ja) | 2021-12-22 | 2025-01-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | Ｋ－ＲＡＳ ＧＴＰａｓｅのＧ１２Ｓ、Ｇ１２Ｄ、及び／又はＧ１２Ｅ変異体の共有結合阻害剤 |
| TW202334155A (zh) * | 2022-01-06 | 2023-09-01 | 美商德洛斯股份有限公司 | 用於抑制ｒａｓ之組合物及方法 |
| US20250188085A1 (en) * | 2022-01-06 | 2025-06-12 | Theras, Inc. | Compositions and methods for inhibition of ras |
| CN118742544A (zh) * | 2022-02-07 | 2024-10-01 | 基因泰克公司 | 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式 |
| JP7749857B2 (ja) * | 2022-02-07 | 2025-10-06 | ジェネンテック， インコーポレイテッド | キナゾリン化合物を合成するための方法 |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| IL315250A (en) | 2022-04-06 | 2024-10-01 | Genentech Inc | Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer |
| IL316696A (en) | 2022-05-19 | 2024-12-01 | Genentech Inc | Azatetracyclic oxazepine compounds and their uses |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| KR20250048078A (ko) | 2022-08-11 | 2025-04-07 | 브리스톨-마이어스 스큅 컴퍼니 | Kras 억제제 |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| KR20250109197A (ko) | 2022-11-21 | 2025-07-16 | 트리라인 바이오사이언시스, 인크. | 스피로환식 디하이드로피라노피리미딘 KRas 억제제 |
| CN115920658B (zh) * | 2023-01-15 | 2023-10-20 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜及其制备方法 |
| WO2024153119A1 (en) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| KR20250151412A (ko) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론계 kras 분해 단백질 및 이와 관련된 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024209717A1 (ja) | 2023-04-06 | 2024-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| WO2025067459A2 (en) | 2023-09-29 | 2025-04-03 | D3 Bio (Wuxi) Co., Ltd. | Therapies for the treatment of cancer |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| US20150087628A1 (en) | 2012-04-10 | 2015-03-26 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| UA119971C2 (uk) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Інгібітори g12c kras |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| EP3280708B1 (en) | 2015-04-10 | 2021-09-01 | Araxes Pharma LLC | Substituted quinazoline compounds and methods of use thereof |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3364977A4 (en) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | PROCESS FOR SCREENING INHIBITORS OF RAS |
| EA038635B9 (ru) | 2015-11-16 | 2021-10-26 | Араксис Фарма Ллк | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| AU2017266911B2 (en) * | 2016-05-18 | 2021-09-02 | Array Biopharma, Inc. | KRas G12C inhibitors |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| SI3710439T1 (sl) | 2017-11-15 | 2023-06-30 | Mirati Therapeutics, Inc., | Zaviralci mutacije kras g12c |
| CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/en active Pending
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/en active Active
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en not_active Ceased
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904A1/en active Pending
- 2024-02-29 IL IL311187A patent/IL311187B1/en unknown
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551065A1 (en) | Fused ring compounds | |
| PH12021500014A1 (en) | Fused ring compounds | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| PH12021551280A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX2020008265A (es) | Derivados farmaceuticos del anillo heterobiciclico 6,5. | |
| PH12021550269A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| MX2022006776A (es) | Composiciones farmaceuticas oftalmicas. | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202090432A1 (ru) | Новые соединения, активирующие путь nrf2 | |
| MX380776B (es) | Derivados de pirazolilaminobenzimidazol como inhibidores de jak. | |
| TH2101002640A (th) | สารประกอบวงแหวนที่เชื่อมกัน | |
| EA202091327A1 (ru) | Макроциклические соединения для лечения заболеваний | |
| EA202192640A1 (ru) | Хинолиновые производные и их применение для лечения рака | |
| EA201892498A1 (ru) | Замещенные карбонуклеозидные производные, приемлемые в качестве противораковых агентов |